US Pharm. 2010;35(3):5.

Atlantic City, NJ -- A New Jersey Superior Court jury found that Hoffmann-La Roche failed to adequately warn Andrew McCarrell's prescribing physician of possible long-term inflammatory bowel disease (IBD) associated with the acne drug Accutane, awarding McCarrell $25.16 million in compensatory damages. McCarrell, prescribed the powerful acne medication at the age of 23, then developed a severe case of IBD and later had his colon removed. The decision follows a string of plaintiffs' wins against Roche over charges that Accutane was a cause of severe bowel maladies, chronic bowel disease, and, in some cases, removal of part or all of plaintiffs' colons and intestines. Roche, which faces as many as 800 cases across the U.S., first advised physicians about a possible association between Accutane and IBD in 1984.